Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RCUS |
---|---|---|
09:32 ET | 8095 | 16.42 |
09:34 ET | 947 | 16.08 |
09:36 ET | 200 | 16.1227 |
09:38 ET | 200 | 16.07 |
09:39 ET | 200 | 16.08 |
09:41 ET | 300 | 16.085 |
09:43 ET | 300 | 16.1 |
09:45 ET | 505 | 16.04 |
09:48 ET | 100 | 16.05 |
09:50 ET | 246 | 16.03 |
09:52 ET | 300 | 16.04 |
09:54 ET | 700 | 16.11 |
09:56 ET | 988 | 15.98 |
09:57 ET | 600 | 15.99 |
09:59 ET | 407 | 15.94 |
10:01 ET | 300 | 15.985 |
10:03 ET | 369 | 16.04 |
10:06 ET | 300 | 15.95 |
10:08 ET | 1400 | 16.04 |
10:10 ET | 1280 | 15.9873 |
10:12 ET | 328 | 15.96 |
10:14 ET | 800 | 15.99 |
10:15 ET | 1300 | 16.015 |
10:17 ET | 345 | 16.04 |
10:19 ET | 200 | 16.03 |
10:21 ET | 300 | 16.05 |
10:24 ET | 200 | 16.03 |
10:26 ET | 1750 | 16.015 |
10:28 ET | 1286 | 15.94 |
10:30 ET | 1083 | 15.91 |
10:32 ET | 200 | 15.89 |
10:33 ET | 400 | 15.88 |
10:35 ET | 335 | 15.91 |
10:37 ET | 100 | 15.88 |
10:39 ET | 800 | 15.9 |
10:42 ET | 300 | 15.87 |
10:44 ET | 2177 | 15.855 |
10:46 ET | 741 | 15.81 |
10:48 ET | 301 | 15.82 |
10:50 ET | 783 | 15.825 |
10:51 ET | 200 | 15.81 |
10:53 ET | 1464 | 15.795 |
10:55 ET | 4007 | 15.8 |
10:57 ET | 1185 | 15.77 |
11:00 ET | 386 | 15.76 |
11:02 ET | 100 | 15.75 |
11:04 ET | 1988 | 15.79 |
11:06 ET | 1907 | 15.76 |
11:08 ET | 100 | 15.74 |
11:09 ET | 104 | 15.74 |
11:11 ET | 1771 | 15.73 |
11:13 ET | 6154 | 15.68 |
11:15 ET | 12496 | 15.665 |
11:18 ET | 3465 | 15.71 |
11:20 ET | 5900 | 15.7117 |
11:22 ET | 14016 | 15.645 |
11:24 ET | 5604 | 15.63 |
11:26 ET | 6848 | 15.62 |
11:27 ET | 200 | 15.61 |
11:29 ET | 300 | 15.61 |
11:31 ET | 7866 | 15.625 |
11:33 ET | 1038 | 15.6 |
11:36 ET | 784 | 15.6 |
11:38 ET | 7153 | 15.6 |
11:40 ET | 3063 | 15.6 |
11:42 ET | 2252 | 15.61 |
11:44 ET | 900 | 15.6099 |
11:45 ET | 400 | 15.59 |
11:47 ET | 11168 | 15.63 |
11:49 ET | 650 | 15.62 |
11:51 ET | 650 | 15.62 |
11:54 ET | 948 | 15.62 |
11:56 ET | 1824 | 15.6201 |
11:58 ET | 5875 | 15.62 |
12:00 ET | 300 | 15.62 |
12:02 ET | 6776 | 15.62 |
12:03 ET | 901 | 15.63 |
12:05 ET | 430 | 15.62 |
12:07 ET | 1889 | 15.61 |
12:09 ET | 600 | 15.618 |
12:12 ET | 1119 | 15.645 |
12:14 ET | 775 | 15.67 |
12:16 ET | 1457 | 15.64 |
12:18 ET | 1006 | 15.64 |
12:20 ET | 300 | 15.64 |
12:21 ET | 3129 | 15.69 |
12:23 ET | 5512 | 15.64 |
12:25 ET | 1395 | 15.64 |
12:27 ET | 11758 | 15.64 |
12:30 ET | 200 | 15.64 |
12:32 ET | 12284 | 15.64 |
12:34 ET | 11160 | 15.54 |
12:36 ET | 578 | 15.56 |
12:38 ET | 900 | 15.57 |
12:39 ET | 6618 | 15.57 |
12:41 ET | 604 | 15.585 |
12:43 ET | 200 | 15.58 |
12:45 ET | 11480 | 15.58 |
12:48 ET | 967 | 15.6 |
12:50 ET | 400 | 15.6 |
12:52 ET | 566 | 15.62 |
12:54 ET | 100 | 15.6 |
12:56 ET | 500 | 15.63 |
12:57 ET | 200 | 15.64 |
12:59 ET | 3566 | 15.61 |
01:01 ET | 400 | 15.62 |
01:03 ET | 1000 | 15.62 |
01:06 ET | 1000 | 15.63 |
01:08 ET | 1640 | 15.66 |
01:10 ET | 300 | 15.68 |
01:12 ET | 1323 | 15.6695 |
01:14 ET | 777 | 15.68 |
01:15 ET | 1216 | 15.72 |
01:17 ET | 400 | 15.7 |
01:19 ET | 710 | 15.7 |
01:21 ET | 600 | 15.69 |
01:24 ET | 9250 | 15.7 |
01:26 ET | 3250 | 15.705 |
01:28 ET | 2676 | 15.7 |
01:30 ET | 200 | 15.69 |
01:32 ET | 1199 | 15.65 |
01:33 ET | 1989 | 15.63 |
01:35 ET | 1500 | 15.63 |
01:37 ET | 900 | 15.64 |
01:39 ET | 200 | 15.63 |
01:42 ET | 200 | 15.62 |
01:44 ET | 4218 | 15.68 |
01:46 ET | 200 | 15.65 |
01:48 ET | 1000 | 15.64 |
01:50 ET | 600 | 15.64 |
01:51 ET | 400 | 15.62 |
01:53 ET | 1412 | 15.62 |
01:55 ET | 908 | 15.64 |
01:57 ET | 600 | 15.65 |
02:00 ET | 1063 | 15.64 |
02:02 ET | 500 | 15.63 |
02:04 ET | 500 | 15.66 |
02:06 ET | 3338 | 15.66 |
02:08 ET | 600 | 15.67 |
02:09 ET | 607 | 15.65 |
02:11 ET | 955 | 15.67 |
02:13 ET | 2500 | 15.705 |
02:15 ET | 200 | 15.7 |
02:18 ET | 300 | 15.71 |
02:20 ET | 100 | 15.71 |
02:22 ET | 1600 | 15.7 |
02:24 ET | 600 | 15.7 |
02:26 ET | 3863 | 15.69 |
02:27 ET | 1391 | 15.69 |
02:29 ET | 400 | 15.69 |
02:31 ET | 2056 | 15.69 |
02:33 ET | 812 | 15.69 |
02:36 ET | 9878 | 15.7 |
02:38 ET | 450 | 15.7 |
02:40 ET | 2443 | 15.63 |
02:42 ET | 400 | 15.62 |
02:44 ET | 1982 | 15.66 |
02:45 ET | 411 | 15.65 |
02:47 ET | 545 | 15.65 |
02:49 ET | 2993 | 15.65 |
02:51 ET | 440 | 15.65 |
02:54 ET | 1023 | 15.64 |
02:56 ET | 1619 | 15.64 |
02:58 ET | 1030 | 15.66 |
03:00 ET | 937 | 15.65 |
03:02 ET | 2534 | 15.64 |
03:03 ET | 2518 | 15.68 |
03:05 ET | 2816 | 15.69 |
03:07 ET | 14988 | 15.79 |
03:09 ET | 1644 | 15.775 |
03:12 ET | 300 | 15.78 |
03:14 ET | 200 | 15.77 |
03:16 ET | 1946 | 15.79 |
03:18 ET | 1058 | 15.8 |
03:20 ET | 550 | 15.86 |
03:21 ET | 1000 | 15.8 |
03:23 ET | 800 | 15.85 |
03:25 ET | 1201 | 15.87 |
03:27 ET | 4054 | 15.835 |
03:30 ET | 500 | 15.83 |
03:32 ET | 2057 | 15.88 |
03:34 ET | 3581 | 15.84 |
03:36 ET | 1350 | 15.81 |
03:38 ET | 2475 | 15.88 |
03:39 ET | 900 | 15.85 |
03:41 ET | 2135 | 15.9 |
03:43 ET | 2219 | 15.87 |
03:45 ET | 3532 | 15.84 |
03:48 ET | 6291 | 15.76 |
03:50 ET | 4290 | 15.74 |
03:52 ET | 6036 | 15.81 |
03:54 ET | 43731 | 15.915 |
03:56 ET | 41231 | 15.93 |
03:57 ET | 51893 | 15.91 |
03:59 ET | 177669 | 15.83 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Arcus Biosciences Inc | 1.5B | -5.1x | --- |
Ardelyx Inc | 1.5B | -20.9x | --- |
Vir Biotechnology Inc | 1.2B | -2.3x | --- |
Arvinas Inc | 1.7B | -4.0x | --- |
Prothena Corporation PLC | 1.2B | -6.4x | --- |
Nurix Therapeutics Inc | 1.2B | -7.8x | --- |
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.5B |
---|---|
Revenue (TTM) | $237.0M |
Shares Outstanding | 91.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.90 |
EPS | $-3.10 |
Book Value | $6.12 |
P/E Ratio | -5.1x |
Price/Sales (TTM) | 6.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -113.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.